• Explore /
  • Poster
  • / Phase 1/2a, open-label, dose-escalation and safety study of APC-100 in men with advanced prostate cancer.

Phase 1/2a, open-label, dose-escalation and safety study of APC-100 in men with advanced prostate cancer.

Abstract Poster

Authors

null

Christos Kyriakopoulos

University of Wisconsin Carbone Cancer Center, Madison, WI

Christos Kyriakopoulos , Elisabeth I. Heath , Jens C. Eickhoff , Jill Kolesar , Mulusew Yayehyirad , Thomas Moll , Glenn Liu

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2015 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

General Poster Session B: Prostate, Penile, Testicular, and Urethral Cancers, and Urothelial Carcinoma

Track

Urothelial Carcinoma,Prostate Cancer,Penile, Urethral, and Testicular Cancers

Sub Track

Prostate Cancer - Advanced Disease

Clinical Trial Registration Number

NCT01436214

Citation

J Clin Oncol 33, 2015 (suppl 7; abstr 234)

DOI

10.1200/jco.2015.33.7_suppl.234

Abstract #

234

Poster Bd #

C3

Abstract Disclosures

Similar Posters

First Author: Giuseppe Del Priore

First Author: Sarah E. R. Halford

First Author: Funda Meric-Bernstam

First Author: Soohyeon Lee